Sanofi said it will pay MannKind as much as $925 million for the global rights to inhaled insulin Afrezza, just a couple months after the treatment received FDA approval. Afrezza is the world's only inhaled insulin, an alternative to injections for adults with diabetes. MannKind will receive an upfront payment of $150 million and milestone payments of up to $775 million, depending on the drug's commercial success. Sanofi and MannKind will share profits and losses on a global basis, with Sanofi retaining 65% and MannKind receiving 35%. Sanofi said the deal is the latest opportunity for the company to bring another insulin option to people with diabetes around the globe.

More from Video

How a Cup of Coffee Brewed the Starbucks Empire

How a Cup of Coffee Brewed the Starbucks Empire

Did Your Employer Make the Best 401(k) Choice?

Did Your Employer Make the Best 401(k) Choice?

Oracle Sees Plenty of Opportunities as the Cloud Evolves

Oracle Sees Plenty of Opportunities as the Cloud Evolves

Davos 2019: Salesforce Co-CEO Reveals What Keeps him Up at Night

Davos 2019: Salesforce Co-CEO Reveals What Keeps him Up at Night

Hey Millennials, Need Some Investing Advice?

Hey Millennials, Need Some Investing Advice?